Public and private institutions both have a role to play in innovation by shaping and creating markets. The question is how public organizations should be structured to better accommodate risk-taking and build the capabilities to manage the challenges created by disruption.
Many Americans have expressed outrage over Pfizer’s plan, through its merger with Allergan, to move its tax home from the United States to Ireland. Now, in a New York Times op-ed, Carl Icahn, the billionaire corporate raider turned hedge fund activist, has joined the chorus. He labels the Pfizer-Allergan deal a “travesty,” blaming the U.S.’s “uncompetitive international tax system.” Read more